Viewing nowBarban Tablets 160 mg (Valsartan)
Valsartan 160mg
Tablet · Prescription medication
Pamgen Science Co., Ltd.

MFDS item code 201602326 · Approved 2016.04.26 · Insurance code 670104010
Treatment of essential hypertension and heart failure, and reduction of the risk of death after myocardial infarction
This medication is used to treat essential hypertension and is also helpful in managing heart failure patients (NYHA class II-IV) who have intolerance to ACE inhibitors. Additionally, it is effective in reducing mortality risk in stable patients with left ventricular dysfunction or impaired contractility after a myocardial infarction. Through these effects, it contributes to improving cardiovascular health.
(Tablets) * 40, 80, 160 mg 1. Essential hypertension Take with water during a meal or between meals. If possible, it is recommended to take the medicine at the same time each day (e.g., in the morning). 1) Adults: The recommended dose is valsartan 80 mg orally once daily, regardless of sex or race. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg per day or a diuretic may be coadministered. If additional blood pressure reduction is required, the dose may be increased to a maximum of 320 mg per day. 2) Elderly patients (75 years of age or older): Initiate treatment with this medicine at 40 mg once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is necessary. (2) Creatinine clearance 10 ∼ 20 mL/min: Initiate treatment with this medicine at 40 mg once daily. (3) Creatinine clearance less than 10 mL/min and patients receiving dialysis: Do not administer this medicine. 4) Patients with intravascular volume depletion: In patients with intravascular volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), initiate treatment with this medicine at 40 mg once daily. 5) Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, initiate treatment with this medicine at 40 mg once daily and do not exceed 80 mg per day. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended initial dose is 40 mg of this medicine orally twice daily, and the dose may be increased to 80 mg or 160 mg per dose. When coadministered with a diuretic, a reduction in the diuretic dose should be considered. The maximum daily dose is 320 mg, given in divided doses. Triple combination therapy with this medicine, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours of the onset of myocardial infarction. The recommended initial dose is 20 mg of this medicine twice daily, and over the following several weeks the dose should be increased according to patient tolerability to 40 mg, 80 mg, and 160 mg per dose twice daily. Consider dose reduction if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients being treated with other therapies after myocardial infarction (e.g., thrombolytic agents, acetylsalicylic acid, beta-blockers, and statins). However, concomitant administration with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is necessary when creatinine clearance is 10 mL/min or greater; however, do not administer this medicine to patients with creatinine clearance less than 10 mL/min or to patients receiving dialysis, as there is no experience with its use in these patients. 5. Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, the daily dose of this medicine should preferably not exceed 80 mg. If administering 80 mg or more per day, consider whether the benefits of increasing the dose outweigh the risks. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis.
Children and adolescents under 18 years of age: Safety and efficacy have not been established.
This medication can cause serious harm to the fetus if taken during pregnancy, especially in the second and third trimesters, so it should be discontinued immediately if pregnancy is confirmed. This medication should not be used in specific patients such as pregnant or potentially pregnant women, nursing mothers, patients with severe liver impairment, or those with severe renal dysfunction. Caution should be exercised when administering this medication to the elderly, patients with hyperkalemia, or those with mild to moderate liver impairment, and their conditions should be closely monitored during treatment. Due to its blood pressure-lowering effects, there is a risk of sudden drops in blood pressure upon initial use, leading to fainting or dizziness. Particularly, patients undergoing dialysis or taking diuretics, and those on strict sodium-restricted diets are at risk of hypotension and should adjust the dosage gradually. This drug can increase potassium levels, so when taken with potassium-sparing diuretics or potassium supplements, serum potassium levels should be monitored carefully. Additionally, interactions may occur when taken with other antihypertensives or non-steroidal anti-inflammatory drugs (NSAIDs), so consultation with a healthcare professional is advised. Since this medication may affect liver and kidney functions, it is important to conduct regular blood tests to monitor renal and hepatic functions. Care should be taken when driving or operating machinery as dizziness or drowsiness may occur. In case of overdose, severe hypotension or reduced consciousness can occur, requiring immediate medical attention. Safety has not been established in children and adolescents, so it is advisable not to use it in this age group. This medication should be stored out of reach of children and not transferred to another container for safety.
Not everyone experiences these, and they can vary from person to person.
This medication is sensitive to air and moisture, so it must be stored in a tightly sealed container. It is important to keep it in a cool place below 30 degrees Celsius to maintain its effectiveness.
An oval film-coated tablet that is orange with a grayish tint
30 tablets per bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowValsartan 160mg
Tablet · Prescription medication
Pamgen Science Co., Ltd.

Valsartan 80mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.

Valsartan 160mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.

Valsartan 40mg
Tablet · Prescription medication
Samsung Novartis Co., Ltd.
Valsartan
Prescription medication
Korea Sandos Co., Ltd.
Valsartan
Prescription medication
Korea Sandos Co., Ltd.

Valsartan
Prescription medication
Korea Sandos Co., Ltd.

Valsartan 320mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.